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Who’s to say that a little light can’t go a long way? Tiny light-emitting diode (LED) chips used to grow plants in space are lighting the 
way for cancer treatment, wound healing, and chronic 
pain alleviation on Earth. 
In 1993, Quantum Devices, Inc. (QDI), of 
Barneveld, Wisconsin, began developing the HEALS 
(High Emissivity Aluminiferous Light-emitting 
Substrate) technology to provide high-intensity, solid-
state LED lighting systems for NASA Space Shuttle 
plant growth experiments. The company evolved out 
of cooperative efforts with the Wisconsin Center for 
Space Automation and Robotics (WCSAR) at the 
University of Wisconsin-Madison—a NASA center for 
the Commercial Development of Space. Ronald W. 
Ignatius, QDI’s president and chairman, represented one 
of WCSAR’s industrial partners at the time. WCSAR 
was conducting research on light sources for promoting 
food growth within closed environments where humans 
would be present for a long duration, such as the Space 
Shuttle and the International Space Station.
With the support of WCSAR, Ignatius experimented 
with LEDs, which provide high-energy efficiency and 
virtually no heat, despite releasing waves of light 10 times 
brighter than the Sun. Ignatius admits that some scien-
tists involved in the project were skeptical at first, think-
ing that the idea of using LEDs to promote plant growth 
was far-fetched. The experiments, however, demon-
strated that red LED wavelengths could boost the energy 
metabolism of cells to advance plant growth and photo-
synthesis. This finding prompted Ignatius to develop a 
line of LED products that emit the exact wavelength of 
light that plants use in photosynthesis.
“Our company gives credit to Dr. Ray Bula, the direc-
tor of WCSAR, for having the foresight to go against the 
prevailing dogma of the time and design the first plant 
experiment using monochromatic light to grow lettuce 
plants,” Ignatius proclaims.
In 1989, Ignatius formed QDI to bring the salt grain-
sized LEDs to market, and in October 1995, the light 
sources made their Space Shuttle flight debut on the 
second U.S. Microgravity Laboratory Spacelab mission 
(STS-73, Columbia).
Partnership
When NASA determined that red LEDs could grow 
plants in space, Marshall Space Flight Center awarded 
QDI several Small Business Innovation Research 
(SBIR) contracts to investigate the effectiveness of the 
broad-spectrum diodes in medical applications. The con-
tracts, issued from 1995 to 1998, focused on increasing 
energy inside human cells. It was NASA’s hope that the 
LEDs would not only yield medical benefits on Earth, but 
that they would help to stem the loss of bone and muscle 
mass in astronauts, which occurs during long periods of 
weightlessness. (In space, the lack of gravity keeps human 
cells from growing naturally.) Furthermore, since wounds 
are slow to heal in a microgravity environment, LED 
therapy could accelerate healing and keep what would 
be termed as minor wounds on Earth from becoming mis-
sion-catastrophic in space. 
In addition to promoting cell growth, the red LEDs 
are capable of activating light-sensitive, tumor-treating 
drugs that, when injected intravenously, could completely 
destroy cancer cells while leaving surrounding tissue virtu-
ally untouched. The technique, approved by the U.S. Food 
and Drug Administration (FDA) for use in laboratory and 
human trials, is known as Photodynamic Therapy. 
With the SBIR assistance from NASA, QDI set out to 
alter a surgical probe that could emit long waves of red 
light to stimulate a Benzoporphyrin-derivative drug called 
Photofrin, which delivers fewer post-operative side effects 
than comparable drugs. Ignatius additionally developed 
a friendly and successful working relationship with Dr. 
Harry Whelan, a professor of pediatric neurology and 
director of hyperbaric medicine at the Medical College of 
Wisconsin in Milwaukee. The two had met after Ignatius 
came across a newspaper article highlighting Whelan’s 
ground-breaking brain cancer surgery technique, which 
uses drugs stimulated by laser lights to accelerate healing. 
Accordingly, QDI provided more than $1.25 million 
from its SBIR contracts to support Whelan’s pioneering 
photobiomodulation research and bring him onboard to 
help improve the surgical probe. 
Collectively, Ignatius, Whelan, and researchers 
from NASA successfully altered the probe for pediat-
ric brain tumors and the prevention of oral mucositis 
(a common side effect of chemotherapy and radiation 
treatments) in pediatric bone marrow transplant patients 
at the Medical College of Wisconsin. In May 1998, a 
20-year-old female became the first patient to undergo 
surgery with the modified probe. The young woman had 
endured six brain surgeries and chemotherapy and radia-
tion treatments over a span of 10 years, but her aggres-
sive cancer kept coming back. Having exhausted all of her 
Red light-emitting diodes are growing plants in space and 
healing humans on Earth. 
Lighting the Way for Quicker, Safer Healing
https://ntrs.nasa.gov/search.jsp?R=20060022057 2019-08-29T21:52:40+00:00Z
 Health and Medicine 7
conventional treatment options, she turned to the NASA-
sponsored Photodynamic Therapy technology. 
During the procedure, surgeons excised as much of 
the recurring brain tumor as they could, then injected 
the light-activated Photofrin into her bloodstream and 
inserted the LED probe into the remaining tumor tissue. 
The probe, which casts long wavelengths that generate 
less heat and penetrate deeper into tissue than the shorter 
wavelengths of traditional medical lasers, proved to be 
both safe and effective, as the tumor never returned and 
the patient recovered with no complications. A second 
operation that took place 3 months later on a male patient 
was also deemed successful by Whelan and his team of 
Medical College of Wisconsin surgeons.
FDA-approved clinical trials continued at several other 
facilities over the next 3 years, including the Roswell 
Park Cancer Institute in Buffalo, New York; Rush-
Presbyterian-St. Luke’s Medical Center in Chicago; and 
the Instituto de Oncologia Pediatrica in Sao Paulo, Brazil. 
QDI became recognized as a U.S. Space Foundation 
“Space Technology Hall of Fame” award recipient in 
2000 and a Marshall Space Flight Center “Hallmark of 
Success” in 2004. 
Product Outcome
The positive clinical trial results, as well as contin-
ued support from NASA and follow-on research grants 
from the Defense Advanced Research Projects Agency, 
helped QDI and the Medical College of Wisconsin 
to fully transition space technology into a new, non-
invasive medical device. The WARP 10 (Warfighter 
Accelerated Recovery by Photobiomodulation) is a 
high-intensity, hand-held, portable LED unit intended 
for the temporary relief of minor muscle and joint pain, 
arthritis, stiffness, and muscle spasms. It also promotes 
relaxation of muscle tissue and increases local blood 
circulation. Unlike the surgical probe, the WARP 10 
does not require intravenous medicine; instead, the unit 
can be placed directly on the skin where treatment is 
to occur.
The WARP 10 was designed to aid armed forces per-
sonnel on the front lines with immediate first aid care for 
minor injuries and pain, thereby improving endurance in 
combat. The “soldier self care” device produces 80 times 
more photon energy than a 250-Watt heat lamp, yet it 
remains cool to the touch. The power advantage reduces 
the time required for each therapeutic dose and provides 
for faster multi-dose exposures when needed, without the 
harmful effects of ultraviolet solar radiation. The U.S. 
Department of Defense and the U.S. Navy are currently 
issuing WARP 10 to crews on submarines and Special 
Forces operations.
QDI has introduced an FDA-approved consumer 
version sharing the same power and properties of the 
military model, as an alternative to the cost and 
complications associated with overuse of non-steroidal 
anti-inflammatory drugs (NSAIDs) for persistent pain 
relief. According to a Mayo Clinic study, adverse events 
associated with the use of NSAIDs are reported more 
frequently to the FDA than such events associated with 
any other group of drugs. Furthermore, conservative 
calculations for the United States estimate that 
approximately 107,000 patients are hospitalized each year 
for NSAID-related gastrointestinal complications and at 
least 16,500 NSAID-related deaths occur annually among 
arthritis patients alone, according to compiled research. 
QDI is shedding the risks and costs linked with these 
anti-inflammatory drugs in favor of shedding light on safe 
and economical human healing.  ❖
HEALS® and WARP 10® are registered trademarks of QDI, Inc.
Photodynamic™ Therapy is a trademark of QDI, Inc.  
Photofrin® is a registered trademark of Axcan Pharma Inc.
The WARP 10 was designed to assist armed forces personnel with immediate ﬁrst aid and care for minor injuries and pain. A 
consumer version is also available.
